51
|
Fernández-Ferreiro A, Luaces-Rodríguez A, Díaz-Tomé V, Gil-Martínez M, Rodríguez Ares MT, Touriño Peralba R, Blanco-Méndez J, González-Barcia M, Otero-Espinar FJ, Lamas MJ. [Cysteamine ophthalmic hydrogel for the treatment of ocular cystinosis]. Farm Hosp 2017; 41:678-687. [PMID: 29112493 DOI: 10.7399/fh.10834] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023] Open
Abstract
Ocular cystinosis is a rare disease characterised by the deposit of cystine crystals on the corneal surface, which hinder patients' eyesight. Oral cysteamine is given as cysteamine; however, it does not reach the cornea due to the lack of corneal vascularization making necessary its administration by the topical ocular route. The aim of the present study is to determine the stability of an ophthalmic hydrogel of cysteamine, which can be potentially prepared at hospital pharmacy departments, under different preservation conditions during a follow-up of 30 days. Different physical and chemical parameters were evaluated: osmolality, pH and cysteamine concentration, which has been measured by a method of ultra performance liquid chromatography-tandem mass spectrometer (UPLC-MS/MS). Descriptive assays were also performed, such as transparency measurement and microbiological assays in order to verify its sterility. The obtained results allow us to conclude that the cysteamine hydrogel is stable during 30 days, being recommendable its preservation in refrigerated conditions.
Collapse
Affiliation(s)
- Anxo Fernández-Ferreiro
- Servicio de Farmacia, Xerencia Xestión Integrada Santiago de Compostela (SERGAS) Grupo Farmacología Clínica, Instituto de Investigación Sanitaria, Santiago de Compostela (IDIS-ISCIII) Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela (USC).
| | - Andrea Luaces-Rodríguez
- Grupo Farmacología Clínica, Instituto de Investigación Sanitaria, Santiago de Compostela (IDIS-ISCIII) Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela (USC).
| | - Victoria Díaz-Tomé
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela (USC).
| | - María Gil-Martínez
- Servicio de Oftalmología, Xerencia Xestión Integrada Santiago de Compostela (SERGAS).
| | | | | | - José Blanco-Méndez
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela (USC).
| | - Miguel González-Barcia
- Servicio de Farmacia, Xerencia Xestión Integrada Santiago de Compostela (SERGAS) Grupo Farmacología Clínica, Instituto de Investigación Sanitaria, Santiago de Compostela (IDIS-ISCIII) Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela (USC).
| | | | - María Jesús Lamas
- Grupo Farmacología Clínica, Instituto de Investigación Sanitaria, Santiago de Compostela (IDIS-ISCIII) Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela (USC).
| |
Collapse
|
52
|
Moscoso A, Ruibal Á, Domínguez-Prado I, Fernández-Ferreiro A, Herranz M, Albaina L, Argibay S, Silva-Rodríguez J, Pardo-Montero J, Aguiar P. Texture analysis of high-resolution dedicated breast 18 F-FDG PET images correlates with immunohistochemical factors and subtype of breast cancer. Eur J Nucl Med Mol Imaging 2017; 45:196-206. [DOI: 10.1007/s00259-017-3830-1] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Accepted: 09/04/2017] [Indexed: 01/28/2023]
|
53
|
Luaces-Rodríguez A, Díaz-Tomé V, González-Barcia M, Silva-Rodríguez J, Herranz M, Gil-Martínez M, Rodríguez-Ares MT, García-Mazás C, Blanco-Mendez J, Lamas MJ, Otero-Espinar FJ, Fernández-Ferreiro A. Cysteamine polysaccharide hydrogels: Study of extended ocular delivery and biopermanence time by PET imaging. Int J Pharm 2017. [DOI: 10.1016/j.ijpharm.2017.06.060] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
54
|
Fernández-Ferreiro A, Luaces-Rodríguez A, Aguiar P, Pardo-Montero J, González-Barcia M, García-Varela L, Herranz M, Silva-Rodríguez J, Gil-Martínez M, Bermúdez MA, Vieites-Prado A, Blanco-Méndez J, Lamas MJ, Gómez-Ulla F, Ruibal Á, Otero-Espinar FJ, González F. Preclinical PET Study of Intravitreal Injections. Invest Ophthalmol Vis Sci 2017; 58:2843-2851. [PMID: 28570736 DOI: 10.1167/iovs.17-21812] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Purpose This work aimed at describing the time course of vitreous clearance through the use of positron emission tomography (PET) as a noninvasive tool for pharmacokinetic studies of intravitreal injection. Methods The pharmacokinetic profile of intravitreal injections of molecules labeled with 18Fluorine (18F) was evaluated in adult Sprague Dawley rats by using a dedicated small-animal PET/computed tomography scanner. Different conditions were studied: three molecules radiolabeled with 18F (18F-FDG, 18F-NaF, and 18F-Choline), three volumes of intravitreal injections (7, 4, and 2 μL), and absence or presence of eye inflammation (uveitis). Results Our results showed that there are significant pharmacokinetic differences among the radiolabeled molecules studied but not among the injected volumes. The presence or absence of uveitis was an important factor in vitreous clearance, since the elimination of the drug was clearly increased when this condition is present. Conclusions Intravitreal pharmacokinetic studies based on the use of dedicated PET imaging can be of potential interest as noninvasive tools in ophthalmic drug development in small animals.
Collapse
Affiliation(s)
- Anxo Fernández-Ferreiro
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain 2Pharmacy Department, Complejo Hospitalario Universitario de Santiago (SERGAS), Santiago de Compostela, Spain 3Molecular Imaging Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain 4Clinical Pharmacology Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Andrea Luaces-Rodríguez
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Pablo Aguiar
- Molecular Imaging Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain 5Molecular Imaging Group, Department of Radiology, Faculty of Medicine, University of Santiago de Compostela, Spain
| | - Juan Pardo-Montero
- Molecular Imaging Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain 6Medical Physics Department, Complejo Hospitalario Universitario de Santiago (SERGAS), Santiago de Compostela, Spain
| | - Miguel González-Barcia
- Pharmacy Department, Complejo Hospitalario Universitario de Santiago (SERGAS), Santiago de Compostela, Spain 4Clinical Pharmacology Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Lara García-Varela
- Molecular Imaging Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Michel Herranz
- Molecular Imaging Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain 7Galician PET Radiopharmacy Unit, Galaria, Complejo Hospitalario Universitario de Santiago (SERGAS), Santiago de Compostela, Spain
| | - Jesús Silva-Rodríguez
- Molecular Imaging Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - María Gil-Martínez
- Service of Ophthalmology, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - María A Bermúdez
- Department of Animal Biology, Vegetal Biology and Ecology, Faculty of Biology, University of A Coruña, A Coruña, Spain
| | - Alba Vieites-Prado
- Clinical Neurosciences Research Laboratory, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - José Blanco-Méndez
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - María Jesús Lamas
- Pharmacy Department, Complejo Hospitalario Universitario de Santiago (SERGAS), Santiago de Compostela, Spain 4Clinical Pharmacology Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Francisco Gómez-Ulla
- Service of Ophthalmology, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain 11Department of Surgery, University of Santiago de Compostela (CIMUS), Spain
| | - Álvaro Ruibal
- Molecular Imaging Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain 5Molecular Imaging Group, Department of Radiology, Faculty of Medicine, University of Santiago de Compostela, Spain 12Nuclear Medicine Department, Complejo Hospitalario Universitario de Santiago (SERGAS), Santiago de Compostela, Spain
| | - Francisco Javier Otero-Espinar
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Francisco González
- Service of Ophthalmology, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain 11Department of Surgery, University of Santiago de Compostela (CIMUS), Spain
| |
Collapse
|
55
|
Fernández-Ferreiro A, Silva-Rodríguez J, Otero-Espinar FJ, González-Barcia M, Lamas MJ, Ruibal A, Luaces-Rodriguez A, Vieites-Prado A, Sobrino T, Herranz M, García-Varela L, Blanco-Mendez J, Gil-Martínez M, Pardo M, Moscoso A, Medín-Aguerre S, Pardo-Montero J, Aguiar P. Positron Emission Tomography for the Development and Characterization of Corneal Permanence of Ophthalmic Pharmaceutical Formulations. Invest Ophthalmol Vis Sci 2017; 58:772-780. [PMID: 28146242 DOI: 10.1167/iovs.16-20766] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Purpose This work is aimed at describing the utility of positron emission tomography/computed tomography (PET/CT) as a noninvasive tool for pharmacokinetic studies of biopermanence of topical ocular formulations. Methods The corneal biopermanence of a topical ophthalmic formulation containing gellan gum and kappa carragenan (0.82% wt/vol) labeled with 18Fluorine (18F) radiotracers (18F-FDG and 18F-NaF) was evaluated by using a dedicated small-animal PET/CT, and compared with the biopermanence of an aqueous solution labeled with the same compounds. Regions of interest (ROIs) were manually drawn on the reconstructed PET images for quantifying the radioactivity concentration in the eye. The biopermanence of the formulations was determined by measuring the radioactivity concentration at different times after topical application. Additionally, cellular and ex vivo safety assays were performed to assess the safety of the performed procedures. Results Differences were observed in the ocular pharmacokinetics of the two formulations. After 1.5 hours of contact, 90% of the hydrogel remained in the ocular surface, while only 69% of the control solution remained. Furthermore, it was observed that flickering had a very important role in the approach of the trial. The application of 18F-FDG in the eye was neither irritating nor cytotoxic for human corneal epithelial cells. Conclusions The use of small-animal PET and 18F radiotracers in ocular pharmacokinetics of ophthalmic formulations is feasible and could be a safe method for future ocular pharmacokinetic studies in humans.
Collapse
Affiliation(s)
- Anxo Fernández-Ferreiro
- Pharmacy and Pharmaceutical Technology Department and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela, Spain 2Pharmacy Department, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Travesía Choupana s/n Santiago de Compostela, Spain 3Molecular Imaging Group, Radiology Deptartment, Universidade de Santiago de Compostela (USC) and Health Research Institute of Santiago de Compostela (IDIS), R/ San Francisco s/n, Santiago de Compostela, Spain 4Clinical Pharmacology Group, University Hospital, Santiago de Compostela (CHUS), Universidade de Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n Santiago de Compostela, Spain
| | - Jesús Silva-Rodríguez
- Molecular Imaging Group, Radiology Deptartment, Universidade de Santiago de Compostela (USC) and Health Research Institute of Santiago de Compostela (IDIS), R/ San Francisco s/n, Santiago de Compostela, Spain
| | - Francisco Javier Otero-Espinar
- Pharmacy and Pharmaceutical Technology Department and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela, Spain
| | - Miguel González-Barcia
- Pharmacy Department, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Travesía Choupana s/n Santiago de Compostela, Spain 4Clinical Pharmacology Group, University Hospital, Santiago de Compostela (CHUS), Universidade de Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n Santiago de Compostela, Spain
| | - María Jesús Lamas
- Pharmacy Department, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Travesía Choupana s/n Santiago de Compostela, Spain 4Clinical Pharmacology Group, University Hospital, Santiago de Compostela (CHUS), Universidade de Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n Santiago de Compostela, Spain
| | - Alvaro Ruibal
- Molecular Imaging Group, Radiology Deptartment, Universidade de Santiago de Compostela (USC) and Health Research Institute of Santiago de Compostela (IDIS), R/ San Francisco s/n, Santiago de Compostela, Spain 5Nuclear Medicine Department and Molecular Imaging Group, University Hospital, Santiago de Compostela (CHUS), Universidade de Santiago de Compostela (USC), Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n Santiago de Compostela, Spain
| | - Andrea Luaces-Rodriguez
- Pharmacy and Pharmaceutical Technology Department and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela, Spain
| | - Alba Vieites-Prado
- Clinical Neurosciences Research Laboratory, University Hospital, Santiago de Compostela (CHUS), Universidade de Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n Santiago de Compostela, Spain
| | - Tomas Sobrino
- Clinical Neurosciences Research Laboratory, University Hospital, Santiago de Compostela (CHUS), Universidade de Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n Santiago de Compostela, Spain
| | - Michel Herranz
- Molecular Imaging Group, Radiology Deptartment, Universidade de Santiago de Compostela (USC) and Health Research Institute of Santiago de Compostela (IDIS), R/ San Francisco s/n, Santiago de Compostela, Spain 5Nuclear Medicine Department and Molecular Imaging Group, University Hospital, Santiago de Compostela (CHUS), Universidade de Santiago de Compostela (USC), Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n Santiago de Compostela, Spain
| | - Lara García-Varela
- Molecular Imaging Group, Radiology Deptartment, Universidade de Santiago de Compostela (USC) and Health Research Institute of Santiago de Compostela (IDIS), R/ San Francisco s/n, Santiago de Compostela, Spain
| | - José Blanco-Mendez
- Pharmacy and Pharmaceutical Technology Department and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela, Spain
| | - María Gil-Martínez
- Ophthalmology Department, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Travesía Choupana s/n Santiago de Compostela, Spain
| | - María Pardo
- Obesidomic Group, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n Santiago de Compostela, Spain
| | - Alexis Moscoso
- Molecular Imaging Group, Radiology Deptartment, Universidade de Santiago de Compostela (USC) and Health Research Institute of Santiago de Compostela (IDIS), R/ San Francisco s/n, Santiago de Compostela, Spain
| | - Santiago Medín-Aguerre
- Galician PET Radiopharmacy Unit, Galaria, University Hospital, Santiago de Compostela (CHUS), Travesía Choupana s/n Santiago de Compostela, Spain
| | - Juan Pardo-Montero
- Molecular Imaging Group, Radiology Deptartment, Universidade de Santiago de Compostela (USC) and Health Research Institute of Santiago de Compostela (IDIS), R/ San Francisco s/n, Santiago de Compostela, Spain 10Medical Physics Department, University Hospital, Santiago de Compostela (CHUS), Travesía Choupana s/n Santiago de Compostela, Spain
| | - Pablo Aguiar
- Molecular Imaging Group, Radiology Deptartment, Universidade de Santiago de Compostela (USC) and Health Research Institute of Santiago de Compostela (IDIS), R/ San Francisco s/n, Santiago de Compostela, Spain 5Nuclear Medicine Department and Molecular Imaging Group, University Hospital, Santiago de Compostela (CHUS), Universidade de Santiago de Compostela (USC), Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n Santiago de Compostela, Spain
| |
Collapse
|
56
|
Fernández-Ferreiro A, Silva-Rodríguez J, Otero-Espinar FJ, González-Barcia M, Lamas MJ, Ruibal A, Luaces-Rodríguez A, Vieites-Prado A, Lema I, Herranz M, Gómez-Lado N, Blanco-Mendez J, Gil-Martínez M, Pardo M, Moscoso A, Cortes J, Sánchez-Martínez M, Pardo-Montero J, Aguiar P. In vivo eye surface residence determination by high-resolution scintigraphy of a novel ion-sensitive hydrogel based on gellan gum and kappa-carrageenan. Eur J Pharm Biopharm 2017; 114:317-323. [DOI: 10.1016/j.ejpb.2017.01.023] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Revised: 01/12/2017] [Accepted: 01/17/2017] [Indexed: 02/02/2023]
|
57
|
Fernández-Ferreiro A, Santiago-Varela M, Gil-Martínez M, González-Barcia M, Luaces-Rodríguez A, Díaz-Tome V, Pardo M, Méndez JB, Piñeiro-Ces A, Rodríguez-Ares MT, Lamas MJ, Otero-Espinar FJ. In VitroEvaluation of the Ophthalmic Toxicity Profile of Chlorhexidine and Propamidine Isethionate Eye Drops. J Ocul Pharmacol Ther 2017; 33:202-209. [DOI: 10.1089/jop.2016.0053] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Affiliation(s)
- Anxo Fernández-Ferreiro
- Department Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
- Department of Pharmacy, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
- Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS-ISCIII), Santiago de Compostela, Spain
| | - María Santiago-Varela
- Department of Ophthalmology, Hospital de Conxo, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
| | - María Gil-Martínez
- Department of Ophthalmology, Hospital de Conxo, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
- Instituto Oftalmológico Gómez-Ulla, Santiago de Compostela, Spain
| | - Miguel González-Barcia
- Department of Pharmacy, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
- Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS-ISCIII), Santiago de Compostela, Spain
| | - Andrea Luaces-Rodríguez
- Department Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
| | - Victoria Díaz-Tome
- Department Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
| | - María Pardo
- Obesidomic Group, Health Research Institute of Santiago de Compostela (IDIS-ISCIII), Santiago de Compostela, Spain
| | - José Blanco Méndez
- Department Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
| | - Antonio Piñeiro-Ces
- Department of Ophthalmology, Hospital de Conxo, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
| | - María Teresa Rodríguez-Ares
- Department of Ophthalmology, Hospital de Conxo, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
| | - Maria Jesus Lamas
- Department of Pharmacy, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
- Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS-ISCIII), Santiago de Compostela, Spain
| | - Francisco J. Otero-Espinar
- Department Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
| |
Collapse
|
58
|
Silva-Rodríguez J, García-Varela L, López-Arias E, Domínguez-Prado I, Cortés J, Pardo-Montero J, Fernández-Ferreiro A, Ruibal Á, Sobrino T, Aguiar P. Impact of benzodiazepines on brain FDG-PET quantification after single-dose and chronic administration in rats. Nucl Med Biol 2016; 43:827-834. [DOI: 10.1016/j.nucmedbio.2016.09.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2016] [Revised: 09/02/2016] [Accepted: 09/07/2016] [Indexed: 02/08/2023]
|
59
|
Fernández-Ferreiro A, González-Barcia M, Gil-Martínez M, Santiago Varela M, Pardo M, Blanco-Méndez J, Piñeiro-Ces A, Lamas Díaz MJ, Otero-Espinar FJ. Evaluation of the in vitro ocular toxicity of the fortified antibiotic eye drops prepared at the Hospital Pharmacy Departments. Farm Hosp 2016; 40:352-70. [PMID: 27570987 DOI: 10.7399/fh.2016.40.5.10416] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The use of parenteral antibiotic eye drop formulations with non-marketed compositions or concentrations, commonly called fortified antibiotic eye drops, is a common practice in Ophthalmology in the hospital setting. The aim of this study was to evaluate the in vitro ocular toxicity of the main fortified antibiotic eye drops prepared in the Hospital Pharmacy Departments. We have conducted an in vitro experimental study in order to test the toxicity of gentamicin, amikacin, cefazolin, ceftazidime, vancomycin, colistimethate sodium and imipenem-cilastatin eye drops; their cytotoxicity and acute tissue irritation have been evaluated. Cell-based assays were performed on human stromal keratocytes, using a cell-based impedance biosensor system [xCELLigence Real-Time System Cell Analyzer (RTCA)], and the Hen's Egg Test for the ocular irritation tests. All the eye drops, except for vancomycin and imipenem, have shown a cytotoxic effect dependent on concentration and time; higher concentrations and longer exposure times will cause a steeper decline in the population of stromal keratocytes. Vancomycin showed a major initial cytotoxic effect, which was reverted over time; and imipenem appeared as a non-toxic compound for stromal cells. The eye drops with the highest irritating effect on the ocular surface were gentamicin and vancomycin. Those antibiotic eye drops prepared at the Hospital Pharmacy Departments included in this study were considered as compounds potentially cytotoxic for the ocular surface; this toxicity was dependent on the concentration used.
Collapse
Affiliation(s)
- Anxo Fernández-Ferreiro
- Pharmacy Unit, Xerencia de Xestión Integrada of Santiago de Compostela, SERGAS, Santiago de Compostela. Clinical Pharmacology Group, Health Research Institute (IDIS-ISCIII), Santiago de Compostela. Department of Pharmacy and Pharmaceutical Technology. School of Pharmacy, Universidad de Santiago de Compostela, Santiago de Compostela..
| | - Miguel González-Barcia
- Pharmacy Unit, Xerencia de Xestión Integrada of Santiago de Compostela, SERGAS, Santiago de Compostela. Clinical Pharmacology Group, Health Research Institute (IDIS-ISCIII), Santiago de Compostela..
| | - María Gil-Martínez
- Ophthalmology Unit, Xerencia de Xestión Integrada of Santiago de Compostela, Santiago de Compostela. Ophthalmological Institute Gómez-Ulla, Santiago de Compostela..
| | - María Santiago Varela
- Ophthalmology Unit, Xerencia de Xestión Integrada of Santiago de Compostela, Santiago de Compostela..
| | - María Pardo
- Obesidomics Group, Health Research Institute (IDIS-ISCIII), SERGAS, Santiago de Compostela. Spain..
| | - José Blanco-Méndez
- Department of Pharmacy and Pharmaceutical Technology. School of Pharmacy, Universidad de Santiago de Compostela, Santiago de Compostela. Industrial Pharmacy Institute, Universidad de Santiago de Compostela (USC), Santiago de Compostela..
| | - Antonio Piñeiro-Ces
- Ophthalmology Unit, Xerencia de Xestión Integrada of Santiago de Compostela, Santiago de Compostela..
| | - María Jesús Lamas Díaz
- Pharmacy Unit, Xerencia de Xestión Integrada of Santiago de Compostela, SERGAS, Santiago de Compostela. Clinical Pharmacology Group, Health Research Institute (IDIS-ISCIII), Santiago de Compostela..
| | - Francisco J Otero-Espinar
- Department of Pharmacy and Pharmaceutical Technology. School of Pharmacy, Universidad de Santiago de Compostela, Santiago de Compostela. Industrial Pharmacy Institute, Universidad de Santiago de Compostela (USC), Santiago de Compostela..
| |
Collapse
|
60
|
Fernández-Ferreiro A, Pose-Reino A, Martinez-Bahamonde F, Paris M, Guemas E, González-Barcia M, Lamas MJ. Serotonin syndrome, rhabdomyolysis and convulsion associated with drug interaction between venlafaxine and amoxicillin/clavulanic acid. Actas Esp Psiquiatr 2016; 44:193-202. [PMID: 27644102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Accepted: 09/01/2016] [Indexed: 06/06/2023]
Affiliation(s)
- Anxo Fernández-Ferreiro
- Servicio de Farmacia, Xerencia Xestión Integrada Santiago de Compostela (SERGAS) Grupo Farmacología Clínica. Instituto de Investigación Sanitaria, Santiago de Compostela (IDIS-ISCIII)
| | - Antonio Pose-Reino
- Unidade Pluripatoloxía e Idade Avanzada, Medicina Interna, Xerencia Xestión Integrada Santiago de Compostela (SERGAS)
| | | | - Marion Paris
- UFR Sciences Pharmaceutiques et Ingiénerie de la Santé, Université d’Angers
| | - Emilie Guemas
- UFR Sciences Pharmaceutiques et Ingiénerie de la Santé, Université d’Angers
| | - Miguel González-Barcia
- Servicio de Farmacia, Xerencia Xestión Integrada Santiago de Compostela (SERGAS) Grupo Farmacología Clínica. Instituto de Investigación Sanitaria, Santiago de Compostela (IDIS-ISCIII)
| | - M J Lamas
- Servicio de Farmacia, Xerencia Xestión Integrada Santiago de Compostela (SERGAS) Grupo Farmacología Clínica. Instituto de Investigación Sanitaria, Santiago de Compostela (IDIS-ISCIII)
| |
Collapse
|
61
|
Fernández-Ferreiro A, Martinez-Bahamonde F, Lopez-Lopez A, Pazos-Simon N, Guemas E, Paris M, Echarri-Arrieta E, Gonzalez-Barcia M, Suarez-Artime P, Lamas M. PS-004 Analysis of the use of psychotropic drugs and pharmacological interactions in spanish chronic psychiatric patients. Eur J Hosp Pharm 2016. [DOI: 10.1136/ejhpharm-2016-000875.489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
62
|
Fernández-Ferreiro A, González-Barcia M, Gil-Martinez M, Garcia-Campos J, Vazquez-Pazos P, Otero-Espinar FJ, Mendez JB, Lamas M. PP-004 Pharmaceutical compounding of 4% lidocaine eye drops as an anaesthesic therapeutic alternative for paediatric patients undergoing examinations or minor ophthalmic surgeries. Eur J Hosp Pharm 2016. [DOI: 10.1136/ejhpharm-2016-000875.443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
63
|
Affiliation(s)
- Anxo Fernández-Ferreiro
- Servicio de Farmacia, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Santiago de Compostela. Grupo de Farmacología Clínica, Instituto de Investigación Sanitaria (IDIS-ISCIII), Santiago de Compostela.Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia , Universidad de Santiago de Compostela (USC), Santiago de Compostela..
| | - Miguel González-Barcia
- Servicio de Farmacia, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Santiago de Compostela. Grupo de Farmacología Clínica, Instituto de Investigación Sanitaria (IDIS-ISCIII), Santiago de Compostela..
| | - Francisco J Otero Espinar
- Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia , Universidad de Santiago de Compostela (USC), Santiago de Compostela. Instituto de Farmacia Industrial, Universidad de Santiago de Compostela (USC), Santiago de Compostela. España..
| | - José Blanco Méndez
- Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia , Universidad de Santiago de Compostela (USC), Santiago de Compostela. Instituto de Farmacia Industrial, Universidad de Santiago de Compostela (USC), Santiago de Compostela. España..
| | - María Jesús Lamas
- Servicio de Farmacia, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Santiago de Compostela. Grupo de Farmacología Clínica, Instituto de Investigación Sanitaria (IDIS-ISCIII), Santiago de Compostela..
| |
Collapse
|
64
|
Fernández-Ferreiro A, Santiago-Varela M, Gil-Martínez M, Parada TGC, Pardo M, González-Barcia M, Piñeiro-Ces A, Rodríguez-Ares MT, Blanco-Mendez J, Lamas MJ, Otero-Espinar FJ. Ocular safety comparison of non-steroidal anti-inflammatory eye drops used in pseudophakic cystoid macular edema prevention. Int J Pharm 2015; 495:680-91. [PMID: 26423177 DOI: 10.1016/j.ijpharm.2015.09.058] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2015] [Revised: 09/22/2015] [Accepted: 09/23/2015] [Indexed: 01/09/2023]
Abstract
Non-steroidal anti-inflammatory drug (NSAID) eye drops are widely used to treat ocular inflammatory conditions related to ophthalmic surgical procedures, such as pseudophakic cystoid macular edema, and they have been used for off-label treatments. The most commonly used NSAIDs are diclofenac and ketorolac and the new molecules bromfenac and nepafenac have also been used. We used primary human keratocytes in cell culture in combination with a novel technology that evaluates dynamic real-time cytotoxicity through impedance analysis. This study also included classic cell viability tests (WST-1(®) and AlamarBlue(®)), wound healing assay, Hen's Egg Test and an ex vivo histopathological assay. NSAIDs were shown to have important cytotoxicities and to retard the healing response. Furthermore, the new eye drops containing bromfenac and nepafenac were more cytotoxic than the more classical eye drops. Nevertheless, no immuno-histochemical changes or acute irritation processes were observed after the administration of any eye drops tested. Due to cytotoxicity and the total absence of discomfort and observable injuries after the administration of these drugs, significant corneal alterations, such as corneal melts, can develop without any previous warning signs of toxicity.
Collapse
Affiliation(s)
- Anxo Fernández-Ferreiro
- Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Santiago de Compostela (USC), Praza Seminario de Estudos Galegos s/n, Santiago de Compostela 1570, Spain; Pharmacy Department, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Travesía Choupana s/n, Santiago de Compostela 15706, Spain; Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS-ISCIII), SERGAS, Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
| | - María Santiago-Varela
- Ophthalmology Department, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Rua Ramón Baltar s/n, Santiago de Compostela 15706, Spain
| | - María Gil-Martínez
- Ophthalmology Department, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Rua Ramón Baltar s/n, Santiago de Compostela 15706, Spain
| | - Tomas García-Caballero Parada
- Pathological Anatomy Department, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Travesía Choupana s/n, Santiago de Compostela 15706, Spain
| | - María Pardo
- Obesidomic Group Instituto de Investigación Sanitaria (IDIS-ISCIII), SERGAS, Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
| | - Miguel González-Barcia
- Pharmacy Department, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Travesía Choupana s/n, Santiago de Compostela 15706, Spain; Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS-ISCIII), SERGAS, Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
| | - Antonio Piñeiro-Ces
- Ophthalmology Department, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Rua Ramón Baltar s/n, Santiago de Compostela 15706, Spain
| | - María Teresa Rodríguez-Ares
- Ophthalmology Department, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Rua Ramón Baltar s/n, Santiago de Compostela 15706, Spain
| | - José Blanco-Mendez
- Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Santiago de Compostela (USC), Praza Seminario de Estudos Galegos s/n, Santiago de Compostela 1570, Spain; Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Praza Seminario de Estudos Galegos s/n, Santiago de Compostela 15701, Spain
| | - M J Lamas
- Pharmacy Department, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Travesía Choupana s/n, Santiago de Compostela 15706, Spain; Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS-ISCIII), SERGAS, Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
| | - Francisco J Otero-Espinar
- Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Santiago de Compostela (USC), Praza Seminario de Estudos Galegos s/n, Santiago de Compostela 1570, Spain; Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Praza Seminario de Estudos Galegos s/n, Santiago de Compostela 15701, Spain.
| |
Collapse
|
65
|
Sánchez-Sánchez MP, Martín-Illana A, Ruiz-Caro R, Bermejo P, Abad MJ, Carro R, Bedoya LM, Tamayo A, Rubio J, Fernández-Ferreiro A, Otero-Espinar F, Veiga MD. Chitosan and Kappa-Carrageenan Vaginal Acyclovir Formulations for Prevention of Genital Herpes. In Vitro and Ex Vivo Evaluation. Mar Drugs 2015; 13:5976-92. [PMID: 26393621 PMCID: PMC4584363 DOI: 10.3390/md13095976] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2015] [Revised: 09/11/2015] [Accepted: 09/15/2015] [Indexed: 11/27/2022] Open
Abstract
Vaginal formulations for the prevention of sexually transmitted infections are currently gaining importance in drug development. Polysaccharides, such as chitosan and carrageenan, which have good binding capacity with mucosal tissues, are now included in vaginal delivery systems. Marine polymer-based vaginal mucoadhesive solid formulations have been developed for the controlled release of acyclovir, which may prevent the sexual transmission of the herpes simplex virus. Drug release studies were carried out in two media: simulated vaginal fluid and simulated vaginal fluid/simulated seminal fluid mixture. The bioadhesive capacity and permanence time of the bioadhesion, the prepared compacts, and compacted granules were determined ex vivo using bovine vaginal mucosa as substrate. Swelling processes were quantified to confirm the release data. Biocompatibility was evaluated through in vitro cellular toxicity assays, and the results showed that acyclovir and the rest of the materials had no cytotoxicity at the maximum concentration tested. The mixture of hydroxyl-propyl-methyl-cellulose with chitosan- or kappa-carrageenan-originated mucoadhesive systems that presented a complete and sustained release of acyclovir for a period of 8–9 days in both media. Swelling data revealed the formation of optimal mixed chitosan/hydroxyl-propyl-methyl-cellulose gels which could be appropriated for the prevention of sexual transmission of HSV.
Collapse
Affiliation(s)
- María-Pilar Sánchez-Sánchez
- Departamento Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, 28040-Madrid, Spain; E-Mails: (M.-P.S.-S.); (A.M.-I.); (R.R.-C.)
| | - Araceli Martín-Illana
- Departamento Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, 28040-Madrid, Spain; E-Mails: (M.-P.S.-S.); (A.M.-I.); (R.R.-C.)
| | - Roberto Ruiz-Caro
- Departamento Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, 28040-Madrid, Spain; E-Mails: (M.-P.S.-S.); (A.M.-I.); (R.R.-C.)
| | - Paulina Bermejo
- Departamento Farmacología, Facultad de Farmacia, Universidad Complutense de Madrid, 28040-Madrid, Spain; E-Mails: (P.B.); (M.-J.A.); (R.C.); (L.-M.B.)
| | - María-José Abad
- Departamento Farmacología, Facultad de Farmacia, Universidad Complutense de Madrid, 28040-Madrid, Spain; E-Mails: (P.B.); (M.-J.A.); (R.C.); (L.-M.B.)
| | - Rubén Carro
- Departamento Farmacología, Facultad de Farmacia, Universidad Complutense de Madrid, 28040-Madrid, Spain; E-Mails: (P.B.); (M.-J.A.); (R.C.); (L.-M.B.)
| | - Luis-Miguel Bedoya
- Departamento Farmacología, Facultad de Farmacia, Universidad Complutense de Madrid, 28040-Madrid, Spain; E-Mails: (P.B.); (M.-J.A.); (R.C.); (L.-M.B.)
| | - Aitana Tamayo
- Instituto de Cerámica y Vidrio, Consejo Superior de Investigaciones Científicas, 28049-Madrid, Spain, E-Mails: (A.T.); (J.R.)
| | - Juan Rubio
- Instituto de Cerámica y Vidrio, Consejo Superior de Investigaciones Científicas, 28049-Madrid, Spain, E-Mails: (A.T.); (J.R.)
| | - Anxo Fernández-Ferreiro
- Departamento Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela, Campus Vida s/n, 15782 Santiago de Compostela, Spain; E-Mails: (A.F.-F.); (F.O.-E.)
| | - Francisco Otero-Espinar
- Departamento Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela, Campus Vida s/n, 15782 Santiago de Compostela, Spain; E-Mails: (A.F.-F.); (F.O.-E.)
| | - María-Dolores Veiga
- Departamento Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, 28040-Madrid, Spain; E-Mails: (M.-P.S.-S.); (A.M.-I.); (R.R.-C.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +34-913-942091; Fax: +34-913-941736
| |
Collapse
|
66
|
Fernández-Ferreiro A, González Barcia M, Gil-Martínez M, Vieites-Prado A, Lema I, Argibay B, Blanco Méndez J, Lamas MJ, Otero-Espinar FJ. In vitro and in vivo ocular safety and eye surface permanence determination by direct and Magnetic Resonance Imaging of ion-sensitive hydrogels based on gellan gum and kappa-carrageenan. Eur J Pharm Biopharm 2015; 94:342-51. [PMID: 26079831 DOI: 10.1016/j.ejpb.2015.06.003] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Revised: 05/20/2015] [Accepted: 06/08/2015] [Indexed: 11/17/2022]
Abstract
Gellan gum, kappa-carrageenan and alginates are natural polysaccharides able to interact with different cations that can be used to elaborate ion-activated in situ gelling systems for different uses. The interaction between fluid solutions of these polysaccharides and cations presents into the tear made these biopolymers very interesting to elaborate ophthalmic drug delivery systems. The main purpose of this study is to evaluate the ability of mixtures of these polymers to obtain ion-activated ophthalmic in situ gelling systems with optimal properties for ocular use. To achieve this purpose different proportion of the biopolymers were analyzed using a mixture experimental design evaluating their transparency, mechanical properties and bioadhesion in the absence and presence of simulated tear fluid. Tear induces a rapid sol-to-gel phase transition in the mixtures forming a consistent hydrogel. The solution composed by 80% of gellan gum and 20% kappa-carrageenan showed the best mechanical and mucoadhesive properties. This mixture was evaluated for rheological behavior, microstructure, cytotoxicity, acute corneal irritancy, ex-vivo and in vivo ocular toxicity and in vivo corneal contact time using Magnetic Resonance Images (MRI) techniques. Result indicates that the system is safe at ophthalmic level and produces an extensive ocular permanence higher than 6h.
Collapse
Affiliation(s)
- Anxo Fernández-Ferreiro
- Pharmacy and Pharmaceutical Technology Department and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela 15782, Spain; Pharmacy Department, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Travesía Choupana s/n, Santiago de Compostela 15706, Spain; Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
| | - Miguel González Barcia
- Pharmacy Department, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Travesía Choupana s/n, Santiago de Compostela 15706, Spain; Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
| | - María Gil-Martínez
- Instituto Oftalmológico Gómez-Ulla, Rúa de Maruxa Mallo, 3, Santiago de Compostela 15706, Spain
| | - Alba Vieites-Prado
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
| | - Isabel Lema
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela 15706, Spain; Surgery Department (Ophthalmology), Faculty of Optics and Optometry, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela 15782, Spain
| | - Barbara Argibay
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
| | - José Blanco Méndez
- Pharmacy and Pharmaceutical Technology Department and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela 15782, Spain
| | - Maria Jesus Lamas
- Pharmacy Department, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Travesía Choupana s/n, Santiago de Compostela 15706, Spain; Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
| | - Francisco Javier Otero-Espinar
- Pharmacy and Pharmaceutical Technology Department and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela 15782, Spain.
| |
Collapse
|
67
|
Fernández-Ferreiro A, Santiago-Varela M, Gil-Martínez M, Pardo-Perez M, González-Barcia M, Piñeiro-Ces A, Blanco-Mendez J, Lamas Díaz MJ, Otero-Espinar F. DI-023 Effect of different antifugal eye drops on human corneal cells in vitro. Eur J Hosp Pharm 2015. [DOI: 10.1136/ejhpharm-2015-000639.201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
68
|
Fernández-Ferreiro A, Suarez-Artime P, Mozo-Penalver H, Echarri-Arrieta E, González-Barcia M, Martinez-Bahamonde F, Campelo-Sanchez E, Lamas Díaz MJ. OHP-008 Ability of a spanish pharmacist registrar to carry out the integral management of a pharmacy department. Eur J Hosp Pharm 2015. [DOI: 10.1136/ejhpharm-2015-000639.456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
69
|
Fernández-Ferreiro A, Fernández Bargiela N, Varela MS, Martínez MG, Pardo M, Piñeiro Ces A, Méndez JB, Barcia MG, Lamas MJ, Otero-Espinar F. Cyclodextrin-polysaccharide-based, in situ-gelled system for ocular antifungal delivery. Beilstein J Org Chem 2014; 10:2903-11. [PMID: 25550757 PMCID: PMC4273241 DOI: 10.3762/bjoc.10.308] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2014] [Accepted: 11/21/2014] [Indexed: 11/23/2022] Open
Abstract
Fluconazole was studied with two different hydrophilic cyclodextrins (hydroxypropyl-β-cyclodextrin (HPBCD) and sulfobutyl ether-β-cyclodextrin (SBECD)) for the formation of inclusion complexes. HPBCD and SBECD showed low cell cytotoxicity in human keratocytes as assessed by the label-free xCELLigence system for real-time monitoring. The fluconazole–HPBCD complex was incorporated into an ion-sensitive ophthalmic gel composed of the natural polysaccharides gellan gum and κ-carrageenan. This system showed good bioadhesive properties and effective control of fluconazole release.
Collapse
Affiliation(s)
- Anxo Fernández-Ferreiro
- Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Santiago de Compostela (USC), Praza Seminario de Estudos Galegos s/n, Santiago de Compostela, 1570, Spain ; Pharmacy Department, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Travesía Choupana s/n, Santiago de Compostela, 15706, Spain
| | - Noelia Fernández Bargiela
- Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Santiago de Compostela (USC), Praza Seminario de Estudos Galegos s/n, Santiago de Compostela, 1570, Spain
| | - María Santiago Varela
- Ophthalmology Department, Hospital de Conxo, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Rua Ramón Baltar s/n, Santiago de Compostela, 15706, Spain
| | - Maria Gil Martínez
- Ophthalmology Department, Hospital de Conxo, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Rua Ramón Baltar s/n, Santiago de Compostela, 15706, Spain
| | - Maria Pardo
- Grupo Obesidomica, Instituto de Investigación Sanitaria (IDIS-ISCIII), SERGAS, Travesía da Choupana s/n, Santiago de Compostela, 15706, Spain
| | - Antonio Piñeiro Ces
- Ophthalmology Department, Hospital de Conxo, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Rua Ramón Baltar s/n, Santiago de Compostela, 15706, Spain
| | - José Blanco Méndez
- Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Santiago de Compostela (USC), Praza Seminario de Estudos Galegos s/n, Santiago de Compostela, 1570, Spain
| | - Miguel González Barcia
- Pharmacy Department, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Travesía Choupana s/n, Santiago de Compostela, 15706, Spain
| | - Maria Jesus Lamas
- Pharmacy Department, Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Travesía Choupana s/n, Santiago de Compostela, 15706, Spain
| | - FranciscoJ Otero-Espinar
- Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Santiago de Compostela (USC), Praza Seminario de Estudos Galegos s/n, Santiago de Compostela, 1570, Spain ; Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Praza Seminario de Estudos Galegos s/n, Santiago de Compostela, 15701, Spain
| |
Collapse
|
70
|
Fernández-Ferreiro A, González Barcia M, Gil Martínez M, Blanco Mendez J, Lamas Díaz MJ, Otero Espinar FJ. [Analysis of ocular toxicity of fluconazole and voriconazole eyedrops using HET-CAM]. Farm Hosp 2014; 38:300-4. [PMID: 25137163 DOI: 10.7399/fh.2014.38.4.7343] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
PURPOSE The objective of the study is to provide toxicological information through the HET-CAM test of Fluconazole and Voriconazole eye drops prepared commonly in Pharmacy Services for the treatment of fungal keratitis. METHOD Experimental Study. The ocular toxicity of topical voriconazole 10 mg/ml and fluconazole 2 mg/ml were evaluated by the hen's egg test (HET) on the chorioallantoic membrane (CAM). The effects on blood vessels were based on its behavior during 300 seconds and processes that may occur at each time, then we calculated the irritation index (is, irritation score). RESULTS AND CONCLUSIONS Both eye drops, voriconazol and fluconazole have been proven to be safe, since the IS that we obtained was zero for both samples and did not present significant signs of irritation. Therefore, these eyedrops are considered suitable for ocular use from a toxicological point of view.
Collapse
Affiliation(s)
- A Fernández-Ferreiro
- Servicio de Farmacia. Hospital Clínico Universitario de Santiago. Gerencia de Gestión Integrada de Santiago de Compostela. Departamento de Farmacia y Tecnología Farmacéutica. Universidad de Santiago de Compostela..
| | - M González Barcia
- Servicio de Farmacia. Hospital Clínico Universitario de Santiago. Gerencia de Gestión Integrada de Santiago de Compostela..
| | - M Gil Martínez
- Especialista en Oftalmología. Universidad de Santiago de Compostela..
| | - J Blanco Mendez
- Departamento de Farmacia y Tecnología Farmacéutica. Universidad de Santiago de Compostela..
| | - M J Lamas Díaz
- Servicio de Farmacia. Hospital Clínico Universitario de Santiago. Gerencia de Gestión Integrada de Santiago de Compostela..
| | - F J Otero Espinar
- Departamento de Farmacia y Tecnología Farmacéutica. Universidad de Santiago de Compostela..
| |
Collapse
|
71
|
Suárez-Artime P, Rodríguez-Prada M, González-Barcia M, Rodríguez-Cobos MS, García-López A, Fernández-Ferreiro A. DI-099 Effectiveness and safety study in children with steroid-dependent nephrotic syndrome treated with levamisole. Eur J Hosp Pharm 2014. [DOI: 10.1136/ejhpharm-2013-000436.270] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
72
|
Fernández-Ferreiro A, Izquierdo-García E, Gomis Muñoz P, Moreno Villares JM, Valero Zanuy MA, León-Sanz M. [Micronutrient supplementation in parenteral nutrition in Spanish hospitals]. NUTR HOSP 2012; 26:566-71. [PMID: 21892576 DOI: 10.1590/s0212-16112011000300020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2010] [Accepted: 04/17/2010] [Indexed: 11/22/2022] Open
Abstract
Several years ago, it was recommended not to add vitamins or oligoelements to parenteral nutrition (PN) solutions and to administer them immediately after the addition of the micronutrients to avoid their decay. Nowadays, it has been observed that with multilayer bags, ternary mixtures and sunlight protection vitamins degradation is minimal. Daily intake of micronutrients is necessary in the critically ill, malnourished or long-term PN patients. Aiming at knowing the schedules of use of micronutrients in PN in Spanish hospitals and the way PN bags are prepared regarding the factors conditioning their stability, we undertook a telephone survey to the pharmacists in charge of PN at the different hospitals. We compared the data obtained with those from other surveys performed in 2001 and 2003. Pharmacists from 97 hospitals answered the questionnaire (answer rate 88%). The hospital sizes ranged 104-1728 beds. As compared to the data form preceding years, we observed a better adequacy to the current recommendations, although there are still 30% of the hospitals that administer micronutrients on an every other day basis independent of the clinical situation of the patients. In most of the hospitals, multilayer bags are used and/or sunlight protection and ternary mixtures. According to these results showing the different criteria for administering vitamins and oligoelements in PN solutions, it seems necessary to elaborate consensus documents that adapt to the reality of the diverse practices besides promoting the performance of well-designed clinical studies establishing the requirements under special clinical situations.
Collapse
|
73
|
Gomis-Muñoz P, Izquierdo-García E, Fernández-Ferreiro A. [Use of organic phosphates and filters in parenteral nutrition in Spanish hospitals]. Farm Hosp 2011; 35:216-7. [PMID: 21489841 DOI: 10.1016/j.farma.2010.09.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2010] [Revised: 09/22/2010] [Accepted: 09/23/2010] [Indexed: 10/18/2022] Open
|
74
|
Izquierdo-García E, Fernández-Ferreiro A, Campo-Angora M, Ferrari-Piquero JM, de Tejada AH. [Satisfaction perceived by outpatients and pharmacy auxiliaries in a Hospital Pharmacy Department, as a method of improving quality]. ACTA ACUST UNITED AC 2011; 26:161-7. [PMID: 21466963 DOI: 10.1016/j.cali.2010.12.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2010] [Revised: 12/04/2010] [Accepted: 12/07/2010] [Indexed: 11/17/2022]
Abstract
OBJECTIVES To evaluate the satisfaction of pharmacy auxiliaries, and patients attending the Outpatient Pharmacy, after the restructuring of the physical space and the process of dispensing drugs. METHODS Three months after the restructuring of the Area (January 2009), we gave satisfaction surveys (anonymously and voluntarily) over 2 weeks, to a sample of the 3,300 patients who came per month and another to pharmacy auxiliaries who had worked in the area. The surveys consisted of eight closed questions with a Likert-type format about the physical space and organization, dispensing process and overall satisfaction (primary endpoint). In addition, there was an open question to gather suggestions. RESULTS A total of 265 patients received the questionnaire (response rate 94%). The most valued aspect was the confidentiality (4.2 ± 0.7) and the worst was the waiting area (3.2 ± 1). There was a 100% response rate from the 26 pharmacy auxiliaries who received the questionnaire. The highest score was obtained by the installation of the bar-code reader (3.9 ± 0.6) and the lowest for organization of the stores (3.1 ± 1.2). They added comments about the lack of personnel, computer systems, organization of space and the lack of clarity of the prescription. The overall patient satisfaction was 4.2 ± 0.6 and that of the auxiliaries was 3.7 ± 0.7. CONCLUSIONS The results of patients and employees satisfaction surveys have been useful information to assess changes in the area and identify points for improvement. In most of the issues the satisfaction was greater in patients than employees. We believe it is necessary to carry out actions for improving physical space and organization.
Collapse
Affiliation(s)
- E Izquierdo-García
- Servicio de Farmacia, Hospital Universitario 12 de Octubre, Madrid, España.
| | | | | | | | | |
Collapse
|
75
|
Izquierdo-García E, Fernández-Ferreiro A, Gomis-Muñoz P, de Tejada AH, Moreno-Villares JM. [Is it worth knowing the characteristics of inpatient paediatric parenteral nutrition?]. An Pediatr (Barc) 2009; 72:116-20. [PMID: 20018577 DOI: 10.1016/j.anpedi.2009.09.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2009] [Revised: 09/28/2009] [Accepted: 09/30/2009] [Indexed: 11/17/2022] Open
Abstract
OBJECTIVE To describe the characteristics of inpatient parenteral nutrition during 2008 in a tertiary level paediatric hospital. To compare this practice with recent standards. MATERIAL AND METHODS Longitudinal, descriptive, and retrospective study of patients under 16 years receiving parenteral nutrition in 2008. Demographic data as well as data of the nutritional support were recorded. RESULTS A total of 120 children received parenteral nutrition, of whom 63 were under 2 years, 30 between 3 and 7 years, and 27 older than 7 years. They accounted for 1.6% of all the inpatients during that period. Most frequent indication was gastrointestinal surgery (35.5%), followed by non-surgical gastrointestinal diseases (19.8%). The average composition in the first day of parenteral nutrition was: 63.1kcal/kg (SD: 21.3); volume, 76.6ml/kg (SD: 28.4); carbohydrates 9.6g/kg/d (SD: 3.2); amino acids 2.1g/kg/d (SD: 0.6), and lipids 1.9g/kg/d (SD: 1). The mean duration of parenteral support was 10.5 days (SD: 9.8). Internal jugular vein (34.7%) and femoral vein were the most common intravenous access. The main reason to discontinue parenteral nutrition was transition to oral/enteral feedings. The complication rate was 27.3%. CONCLUSIONS There is an interest in evaluating standard practice in parenteral nutrition in order to develop improvement strategies. Infants and toddlers are the principal candidates for parenteral nutrition. Standardisation is one way to decrease errors in its preparation and prescription.
Collapse
Affiliation(s)
- E Izquierdo-García
- Servicio de Farmacia, Hospital Universitario 12 de Octubre, Madrid, España
| | | | | | | | | |
Collapse
|